Analyst Price Target is $4.20
▲ +511.35% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Codiak BioSciences in the last 3 months. The average price target is $4.20, with a high forecast of $7.00 and a low forecast of $1.40. The average price target represents a 511.35% upside from the last price of $0.69.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Codiak BioSciences. This Buy consensus rating has held steady for over two years.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.